The Food and Drug Administration (FDA) announced a new proposal Monday for flexible drug approval pathway treatments addressing ultrarare diseases. The FDA unveiled draft guidance on a proposed ...
San Diego – Officials from the European Medicines Agency (EMA) discussed the different types of expedited approval pathways available to sponsors of innovative drugs and advanced therapy medicinal ...
San Diego – The US Food and Drug Administration’s (FDA) top biologics official said the proposed Promising Pathways Act would lower the bar for approving treatments for rare diseases and that the ...
FDA is proposing the PM pathway largely in response to concerns from patient advocates and industry stakeholders that FDA’s existing product approval pathways lack sufficient flexibility for ...
After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, ...
Zongertinib gained accelerated approval for unresectable/metastatic HER2 kinase-domain–mutant nonsquamous NSCLC, with 76% ORR and DOR ≥12 months in 44%. AMPLIFY ...
For manufacturers, medical device companies, and laboratories that use the commercial diagnostic tests they produce, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results